info@biomedres.us   +1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Transcriptional Expressions of YTHDF 1/2/3 as Prognosis Indicators for Survivals in Lung Adenocarcinoma Patients

Volume 45 - Issue 5

Zhicheng Huang1, Aimee L Hong2, Jian Chen3, Xi Chen1, Lei Yang1, Hang Li4* and Zhiqiang Sun3*

  • Author Information Open or Close
    • 1Department of Radiology, Jilin Province Cancer Hospital, China
    • 2New Trier High School, USA
    • 3Department of Interventional Radiology, China
    • 4Department of Thoracic Oncology, Jilin Province Cancer Hospital, China
    • *Corresponding author: Hang Li, Department of Thoracic Oncology, Jilin Province Cancer Hospital, 1018 lake road, Changchun, Jilin, China

      Zhiqiang Sun, MD, Department of Interventional Radiology, Jilin Province Cancer Hospital, Changchun, Jilin, China 1018 lake road, Changchun, Jilin, China

Received: July 07, 2022;   Published: August 24, 2022

DOI: 10.26717/BJSTR.2022.45.007255

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Background and Methods: N6-methyladenosine (m6A) is the most prevalent and abundant post-transcriptional RNA modification in eukaryotic mRNA. YTHDFs, as m6A readers, destabilize m6A-containing mRNAs and play an important role in the tumorigenesis and metastasis of multiple malignancies. However, knowledge regarding the YTHDF homology in connection to non-small cell lung cancer (NSCLC) is still inconclusive. This study systematically analyzed the expression profiles and prognostic values of the YTHDF family in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients, by using ONCOMINE, UALCAN, Kaplan-Meier Plotter, cBioPortal, GePIA 2.0 and Network analyst databases.

Results: The mRNA of the YTHDF family was over-expressed in both LUAD and LUSC. Lower YTHDF1 (HR 0.48, 95% CI:0.38-0.61, P=1e-9), YTHDF2 (HR 0.47, 95% CI: 0.37-0.6, P=3.3e-10), YTHDF3 (HR 0.44, 95% CI: 0.35-0.56, P=1.1e-11) mRNA expression was significantly associated with worse overall survival (OS) in the LUAD patients, but not in LUSC patients. The expressions of YTHDF1,2,3 were highly mutated in LUAD patients, with YTHDF1, YTHDF2, and YTHDF3 gene mutation rates being 36%, 19%, and 32%, respectively. In addition, the prognostic value of YTHDFs in the different clinicopathological features based on intrinsic subclasses and treatments of LUAD patients was further assessed in the KM plotter database.

Conclusion: Our studies elucidate the expression and prognostic role of YTHDFs in NSCLC. Our results indicated that mRNA expression of YTHDF1, YTHDF2, YTHDF3 is a potential predictor of outcomes for LUAD patients, but not in LUSC patients. These data suggest that YTHDFs would be potential prognostic biomarkers and novel therapeutic targets for LUAD patients.

Keywords: YTHDF; m6A RNA; LUAD; NSCLC; Prognostic Role

Introduction| Materials and Methods| Results| Discussion| Disclosure| References|